stockportfolio.pro
Stocks / CATX vs LAB
CATX vs LAB
Perspective Therapeutics, Inc. and Standard BioTools Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Perspective Therapeutics, Inc. (CATX) | Standard BioTools Inc. (LAB) | |
|---|---|---|
| Market cap | $0.3B | $0.3B |
| Revenue (latest FY) | $884,000 | $85.33M |
| Net income (latest FY) | $-103.12M | $-74.90M |
| Revenue growth (5y CAGR) | -38.5% | -9.2% |
| Net margin | -11665.3% | -87.8% |
| Return on equity | -49.8% | -17.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CATX — free Open LAB — freeFrequently asked questions
Which is bigger, CATX or LAB?
Standard BioTools Inc. is larger by market capitalization — $0.3B versus $0.3B.
Which grows faster, CATX or LAB?
Over the last five fiscal years, Standard BioTools Inc. grew revenue faster — -9.2%/yr versus -38.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.